non-small cell lung cancer

Daiichi Sankyo and Thermo Fisher Partner on Companion Diagnostic Device for NSCLC
Daiichi Sankyo and Thermo Fisher Partner on Companion Diagnostic Device for NSCLC
BioSpace
Daiichi Sankyo
Thermo Fisher
companion diagnostics
diagnostics
non-small cell lung cancer
Flag link:
NICE backs funding for Roche’s lung cancer drug after price cut
NICE backs funding for Roche’s lung cancer drug after price cut
Pharmaforum
NICE
Roche
Rozlytrek
non-small cell lung cancer
Flag link:
Marketing Lilly's Cyramza, after split decision from FDA advisers, wins first-line lung cancer nod
Marketing Lilly's Cyramza, after split decision from FDA advisers, wins first-line lung cancer nod
Fierce Pharma
Eli Lilly
Cyramza
FDA
non-small cell lung cancer
Flag link:
Ahead of ASCO, Bristol Myers Squibb Announces Results for Three Clinical Trials
Ahead of ASCO, Bristol Myers Squibb Announces Results for Three Clinical Trials
BioSpace
Bristol-Myers Squibb
Opdivo
Yervoy
non-small cell lung cancer
ide-cel
Multiple Myeloma
Bluebird Bio
ASCO 2020
Flag link:
Novartis Drug Wins FDA Approval for Lung Cancers With Specific Mutation
Novartis Drug Wins FDA Approval for Lung Cancers With Specific Mutation
Xconomy
Novartis
Tabectra
FDA
non-small cell lung cancer
capmatinib
Flag link:
AstraZeneca stops lung cancer trial early, after star drug Tagrisso induces 'overwhelming' efficacy
AstraZeneca stops lung cancer trial early, after star drug Tagrisso induces 'overwhelming' efficacy
Endpoints
AstraZeneca
Tagrisso
clinical trials
non-small cell lung cancer
Flag link:
BMS' Opdivo gets another lung cancer shot as FDA, EMA accept chemo combo filings
BMS' Opdivo gets another lung cancer shot as FDA, EMA accept chemo combo filings
Fierce Pharma
Bristol-Myers Squibb
Opdivo
Yervoy
non-small cell lung cancer
FDA
Europe
priority review
EMA
Flag link:
In two-man race with Novartis, Merck scores first regulatory approval for targeted lung cancer drug
In two-man race with Novartis, Merck scores first regulatory approval for targeted lung cancer drug
Endpoints
Novartis
Merck KGaA
Japan
tepotinib
non-small cell lung cancer
Flag link:
Lilly’s Cyramza closer to first-line lung cancer use after ODAC verdict
Lilly’s Cyramza closer to first-line lung cancer use after ODAC verdict
Pharmaforum
Eli Lilly
Cyramza
non-small cell lung cancer
FDA
advisory panels
Flag link:
Takeda’s ALUNBRIG gets FDA priority review for expanded indication in NSCLC
Takeda’s ALUNBRIG gets FDA priority review for expanded indication in NSCLC
Pharmaceutical Business Review
Takeda
Alunbrig
brigatinib
FDA
priority review
non-small cell lung cancer
Flag link:
FDA Grants Priority Review to Roche's Lung Cancer Drug Tecentriq
FDA Grants Priority Review to Roche's Lung Cancer Drug Tecentriq
Motley Fool
Roche
FDA
priority review
Tecentriq
non-squamous non-small cell lung cancer
non-small cell lung cancer
Flag link:
Novartis nabs priority review for a blockbuster-to-be aimed at NSCLC niche — delighting Incyte execs
Novartis nabs priority review for a blockbuster-to-be aimed at NSCLC niche — delighting Incyte execs
Endpoints
Incyte
Novartis
FDA
capmatinib
prioirty review
non-small cell lung cancer
Flag link:
Bristol-Myers Withdraws European Application for Lung Cancer Combo
Bristol-Myers Withdraws European Application for Lung Cancer Combo
Motley Fool
Bristol-Myers Squibb
Europe
Opdivo
Yervoy
non-small cell lung cancer
Flag link:
Racing Blueprint, Lilly drug gets priority review for RET hopeful
Racing Blueprint, Lilly drug gets priority review for RET hopeful
Fierce Biotech
Eli Lilly
FDA
Blueprint Medicines
selpercatinib
LOXO-292
thyroid cancer
non-small cell lung cancer
Flag link:
BeiGene’s Tislelizumab Could Challenge Merck’s Keytruda in the Checkpoint Inhibitor Market
BeiGene’s Tislelizumab Could Challenge Merck’s Keytruda in the Checkpoint Inhibitor Market
BioSpace
BeiGene
tiselizumab
non-small cell lung cancer
Merck
Keytruda
Flag link:
Spectrum Pharma Shares Slump After Lung-Cancer Drug Doesn't Meet Phase II Endpoint
Spectrum Pharma Shares Slump After Lung-Cancer Drug Doesn't Meet Phase II Endpoint
TheStreet.com
Spectrum Pharma
lung cancer
clinical trials
poziotinib
non-small cell lung cancer
Flag link:
ESMO I-O: Roche silences Tecentriq doubters with latest lung cancer analysis
ESMO I-O: Roche silences Tecentriq doubters with latest lung cancer analysis
Fierce Pharma
ESMO
Roche
Tecentriq
non-small cell lung cancer
Flag link:
AZ’s Imfinzi approved in early lung cancer in China
AZ’s Imfinzi approved in early lung cancer in China
Pharmaforum
China
AstraZeneca
Imfinizi
non-small cell lung cancer
Flag link:
Merck's Keytruda lung cancer sales may face new pressure, but investors shouldn't sweat it: analyst
Merck's Keytruda lung cancer sales may face new pressure, but investors shouldn't sweat it: analyst
Fierce Pharma
Merck
Keytruda
non-small cell lung cancer
Flag link:
AstraZeneca, on BMS' heels, scores lung cancer win with Imfinzi combos
AstraZeneca, on BMS' heels, scores lung cancer win with Imfinzi combos
Fierce Pharma
AstraZeneca
Imfinizi
non-small cell lung cancer
Flag link:

Pages